Navigation Links
Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
Date:4/7/2013

our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) positive preclinical efficacy findings, such as those for NKTR-214 reported in this press release, are subject to inherent scientific and medical uncertainties typical for this stage of drug development and may not be confirmed in subsequent preclinical studies or in clinical trials; (ii) NKTR-214 is in early stage research and there are a number of hurdles, including the successful completion of preclinical toxicology studies, prior to NKTR-214 being ready to enter into clinical development; (iii) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (iv) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approv
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
2. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
3. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
4. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
9. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
10. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Provectus Biopharmaceuticals, ... therapies. PV-10, its novel investigational drug for cancer, is ... for systemic side effects. Its oncology focus is on ... has completed phase 2 trials of PV-10 as a ... topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... leading biopharmaceutical company dedicated to the research and development ... disorders, is marking Digestive Disease Week (DDW) 2012 in ... lives of patients with Crohn,s disease. UCB will present ... "DDW is an exciting opportunity for UCB to ...
... 17, 2012  Eisai announced today that 15 abstracts highlighting new ... Annual Meeting of the American Society of Clinical Oncology (ASCO), ... 2012. These studies highlight Eisai,s current product ... and their families affected by cancer. "Our ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 2UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 3UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 2Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 3Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 5Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 6Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 7Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 8Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 9
(Date:10/22/2014)... Austin, TX (PRWEB) October 22, 2014 ... Criminal Minds featuring skin diseases both fictional ... Foundation (CEHMDF), a nonprofit organization committed to advocacy ... wondering if CBS will take the opportunity to impart ... disease. , There are many misconceptions about ...
(Date:10/22/2014)... Norton HealthDay Reporter , TUESDAY, ... the three Ebola cases in Dallas. But, mental health specialists ... Americans. President Barack Obama on Friday appointed an Ebola ... has infected two Dallas nurses who cared for a Liberian ... Presbyterian Hospital. But the U.S. cases are miniscule in ...
(Date:10/22/2014)... Hay House is pleased to announce the official release ... (Paperback; $10.82) written by the highly esteemed Tommy Rosen, leader ... is meant to help readers of all kinds end their ... Recovery 2.0 is not the average self-help book, or a ... for what comes next. For many, Alcoholics Anonymous ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... and the Virgin Mary, Paris Hilton has now turned to ... a 100-count thread . ,The socialite has apparently ... her deal with her prison ordeal. ,According to ... she is psychologically still very weak and is holding on ...
... For the first time, an Indian weather station is ... the impact of climate change and provide weather details ... setting up an Integrated Sensor Suite (ISS), a warning ... weather station, at the Chhota Shigri glacier in Himachal ...
... said they could consider closing down a hospital at the ... left to die on the floor of the emergency room. ... by the Los Angeles County department of Health ... and minorities in South Los Angeles. Predictably it has been ...
... Institute for Health and Clinical Excellence (Nice)s suggestion for ... the NHS .,TWENTY thousand people will be condemned to ... decision is implemented, they contended. , ,Both ... all types of wet age-related macular degeneration (AMD), ...
... slowing down in some African countries due to a series ... Bank report as saying . ,According to the ... Kenya, Zimbabwe and urban areas of Ethiopia, Rwanda, Burundi and ... communities are empowered to help themselves with better delivery of ...
... you a doctor, with expertise in anesthetics and obstetrics? You ... ,You can then make a beeline for Temora, a ... Peter Speirs is offering you half a million dollars. ... person, expectant mothers will have to travel an extra 80 kilometres ...
Cached Medicine News:Health News:Indian Weather Station Near Glacier to Study Global Warming 2Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 2Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 3Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 4Health News:UK Suggestion for Restricted Use of Anti-AMD Drugs Draws Flak 2Health News:UK Suggestion for Restricted Use of Anti-AMD Drugs Draws Flak 3Health News:Half a Million Dollars Offered for GPs With Expertise in Anesthetics and Obstetrics 2
... Blood Collection Needle consists of a BD ... safety shield aligned to the bevel-up position. ... Eclipse Blood Collection Needle has its safety ... attach a secondary safety accessory. Immediate, one-handed ...
37°C incubator for DianaGel cards....
ScanGel® Incubator...
... runs up to 12 mini gels under ... gels can be poured 12 at a ... former and Mini-PROTEAN 3 multi-casting chamber, eliminating ... Ready Gel precast gels offer the convenience ...
Medicine Products: